Abcam, ab251554, Anti-Obestatin antibody [EPR19972] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GHRL antibody. Carrier free. Suitable for WB, IHC-Fr, IHC-P and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19972,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:WB, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251554 is the carrier-free version of
ab216575
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Obestatin also known as the obestatin hormone is a 23-amino acid peptide with a mass of approximately 2.5 kDa. Researchers discovered it as a cleavage product from the Ghrelin preprohormone. Obestatin is mainly expressed in the stomach and small intestine but one can also find it in other tissues such as the pancreas and adipose tissue. This peptide acts mechanically by binding to its receptor GPR39 although the binding affinity and downstream effects remain subjects of investigation.
Biological function summary
This peptide hormone interacts with several bodily processes mostly related to gastrointestinal functions and energy homeostasis. It does not form part of a larger protein complex but acts independently. Studies suggest it could play roles in reducing food intake and slowing down gastric emptying potentially contrasting the action of Ghrelin which stimulates hunger. Understanding its precise biological role remains complex with ongoing research needed to clarify its function fully.
Pathways
Several metabolic circuits include obestatin within their framework. It engages in pathways associated with energy balance and gut motility. In relation to the ghrelin axis specialists evaluate its potential modulatory effects given its origin from the same precursor. So far research indicates possible interplay with pathways influencing insulin release although the mechanistic details are not yet fully understood.
Preliminary research indicates obestatin might have connections to obesity and metabolic syndrome. Some scholars propose a potential protective effect against weight gain but findings often vary. Obestatin's relationship with the aforementioned diseases might involve its interaction with ghrelin highlighting a complex regulatory network that warrants further investigation. These insights could lead to novel therapeutic avenues for tackling metabolic disorders.